As MACRA Implementation Proceeds, Changes Are Needed

MACRA threatens to push many providers out of fee-for-service before they have a safe place to land. Policy makers should consider both making the Merit-Based Incentive Payment System less onerous and greatly accelerating the development and implementation of viable alternative payment models.

April 21, 2017

The Future Of Delivery System Reform

There is bipartisan agreement on the goal of promoting more efficient and effective health care. The debate is over the best way to accomplish the goal, not the goal itself.

April 20, 2017

The Payment Reform Landscape: The Potential Value Of Aligning High-Value Benefit Designs With Payment Reforms

While payment reform efforts are proliferating, one thing we see often is a mismatch between the incentives offered to health care providers and those offered to their patients, who may not be driven to seek care from practices that have restructured to provide higher value care.

April 4, 2017

Overcoming Challenges Of Outcomes-Based Contracting For Pharmaceuticals: Early Lessons From The Genentech–Priority Health Pilot

Scientific investments have led to breakthroughs not previously imaginable. However, treating people with serious diseases such as cancer is expensive. The Genentech–Priority Health outcomes-based pilot sought to move beyond the transactional nature of payer–pharma relationships to build a...

April 3, 2017

Taming Health Care Spending: Could State Rate Setting Work?

For more than three and a half decades health care expenditures in the United States have grown at a much higher rate than those in other wealthy nations. To get a handle on prices, policymakers should seriously consider rate regulation.

March 20, 2017

Innovation In Serious Illness Care Payment: Progress To Date And Opportunities For The New Administration

Discern Health recently developed a framework of principles for payment models to promote the delivery of community-based, comprehensive, high-quality, affordable serious illness care. Here are some key opportunities for policymakers to continue progress toward high-value care for the seriously ill.

March 8, 2017

R&D Costs For Pharmaceutical Companies Do Not Explain Elevated US Drug Prices

The pharmaceutical industry often explains that the higher prices they charge in the US provide them with the funds they need to conduct their high-risk research. This claim is empirically testable.

March 7, 2017

Obstacles On The Road To Risk

A recent survey of American Medical Group Association members showed that health systems across the nation still see the destination called value as a distant sign still ahead of us.

February 15, 2017

Tucked Away In The Cures Act, A Better Option For Addressing Readmission Penalties For Safety-Net Providers

The Cures Act---in contrast to prior proposals, which argued for changes to the readmission measures---directly mitigates the impact of penalties on safety-net hospitals.

February 7, 2017

What Is The ‘Relative Value’ Of An Infectious Disease Physician?

In the 2016 internal medicine fellowship match, in which residents were matched with subspecialty training programs, 35 percent of available ID training positions nationwide were left unfilled.

February 3, 2017